期刊文献+

髓母细胞瘤β-catenin蛋白表达与10q杂合性缺失检测及其临床意义 被引量:3

Clinicopathoiogic significance of β-catenin protein and loss of heterozygosity on lOq in meduUoblastoma
原文传递
导出
摘要 目的探讨髓母细胞瘤β-catenin蛋白的表达及10q杂合性缺失与临床病理特征的关系。方法选择新疆医科大学第一附属医院2002至2011年间,经病理组织学诊断为不同类型的髓母细胞瘤合计50例,包括经典型髓母细胞瘤32例,促纤维增生型13例,结节型5例,采用免疫组织化学EnVision法对50例髓母细胞瘤石蜡切片β-catenin蛋白进行半定量分析,荧光原位杂交技术检测10q杂合性缺失,Kaplan-Meien和Cox回归分析β-catenin蛋白、10q杂合性缺失与临床病理特征及预后关系。结果β-catenin蛋白在经典型髓母细胞瘤胞质中阳性率为53.1%(17/32),促纤维增生型为4/13,广泛结节型为1/5;经典髓母细胞瘤10q杂合性缺失率为33.3%(8/24),促纤维增生型为2/11,结节型未见10q杂合性缺失(0/5);三种类型间比较,差异均无统计学意义(P〉0.05)。单因素分析B.catenin蛋白阳性表达者(P=0.022)、无10q杂合性缺失(P=0.020)、肿瘤切除范围(P〈0.01)、放疗(P=0.002)、化疗(P〈0.01)与髓母细胞瘤患者预后相关。结论β-catenin蛋白阳性表达者、无10q杂合性缺失者预后较好。检测髓母细胞瘤染色体β-eatenin蛋白表达和10q杂合性缺失,有助于预后判断。 Objective To study the expression of β-catenin protein and the status of loss of heterozygosity (LOH) on chromsome 10q in medulloblastoma, with clinical correlation. Methods Immunohistochemical study for β-eatenin protein was carried out in 50 cases of medulloblastoma encountered in the First Affiliated Hospital of Xinjiang Medical University during the period from 2002 to 2011, including 32 cases of classic medulloblastoma, 13 cases of desmoplastic medulloblastoma and 5 cases of medulloblastoma with extensive nodularity. The status of LOH on 10q was also detected by fluorescence in-situ hybridization. The clinicopathologic characteristics and prognostic parameters were studied by Kaplan- Meien and Cox analysis. Results The rates of expression of 13-catenin protein in classic medulloblastoma, desmoplastie medulloblastoma and medulloblastoma with extensive nodularity were 53.1% (17/32), 4/13 and 1/5, respectively. The rate of LOH on 10q was 33.3% (8/24) in classic medulloblastoma and 2/11 in desmoplastic medulloblastoma. There was no statistically significant difference between the two tumor types. Univariate analysis showed that the expression of β-catenin protein ( P = 0. 022 ), lack of LOH on 10q ( P = 0. 020), extensiveness of tumor resection ( P 〈 0. 01 ), radiotherapy ( P = 0. 002 ) and chemotherapy (P 〈 0.01 ) represented important prognostic factors. Conclusions Medulloblastoma with expression of β-eatenin protein and without LOH on 10q carries a better prognosis. Assessment of these parameters is helpful in evaluating prognosis and subsequent patient management.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2012年第12期823-827,共5页 Chinese Journal of Pathology
关键词 髓母细胞瘤 杂合子丢失 预后 Medulloblastoma Loss of heterozygosity Prognosis
  • 相关文献

参考文献21

  • 1Brandes AA, Franceschi E, Tosoni A, et al. Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol,2009, 71 (2) : 165-179.
  • 2Maruyanaa K, Ochiai A, Akimoto S, et al. Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology,2000,59 (4) :302 -309.
  • 3Brat DJ, Seiferheld WF, Perry A, et al. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro Oncol, 2004,6 (2) :96-103.
  • 4Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of tumours of the central nervous system. Lyon : IARC Press, 2007 : 132-140.
  • 5Korshunov A, Savostikova M, Ozerov S. Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrKC, and c-myc expression. J Neurooncol, 2002,58 (3) :271-279.
  • 6McManamy CS, Pears J, Weston CL, et al. Nodule formation and desmoplasia in medulloblastomas : defining the nodular/ desmoplastic variant and its biological behaviour. Brain Pathol,2007,17(2) :151-164.
  • 7Matsubayashi S, Nakashima M, Kumagai K, et al. Immuohistochemieal analyses of beta-eatenin and eyelin D1 expression in giant cell tumor of bone (GCTB) :a possoble role of Wnt pathway in GCTB tumorgenesis. Pathol Res Pract,2009,205 (9) :626-633.
  • 8武文浩,马俊艳,万虹,历俊华,张力伟.β-catenin和Ki-67在脑干胶质瘤中的表达及意义[J].中国微侵袭神经外科杂志,2010,15(4):172-174. 被引量:7
  • 9吴湘如,朱明华,张忠德,殷敏智,奚政君,张凤英,张文竹.E-cadherin、β-catenin在神经母细胞瘤中的异常表达及其与临床病理参数的关系[J].中华病理学杂志,2007,36(3):155-159. 被引量:4
  • 10Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol,2007 ,4 (5) :295-304.

二级参考文献31

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1366
  • 2Kleihues P,Cavenee WK.World Health Organization classification of toumrs.Pathology and genetics of tumors of the nervous system[M].Lyon:IARC Press,2000:129-37.
  • 3Biegel JA,Rorke LB,Packer RJ,et al.Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system[J].Genes Chromosomes Cancer,1989,1:139-47.
  • 4Reardon DA,Michalkiewicz E,Boyett JM,et al.Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization[J].Cancer Res,1997,57:4042-7.
  • 5Chmidt EE,Ichimura K,Goike HM,et al.Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts[J].J Neuropathol Exp Neurol ,1999,58:1170-83.
  • 6Ye Z,Wu JK,Darras BT.Loss of heterozygosity for alleles on chromosome 10 in human brain tumours[J].Neurol Res,1993,15:59-62.
  • 7Blaeker H,Rasheed BK,McLendon RE,et al.Microsatellite analysis of childhood brain tumors[J].Genes Chromosomes Cancer,1996,15:54-63.
  • 8Scheurlen WG,Schwabe GC,Joos S,et al.Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome[J].J Clin Oncol,1998,16:2478-85.
  • 9Mollenhauer J,Wiemann S,Scheurlen W,et al.DMBT1,a new member of the SRCR superfamily,on chromosome 10q25.3-26.1 is deleted in malignant brain tumours[J].Nature Genet,1997,17:32-9.
  • 10Ahmed Rasheed BK,Stenzel TT,McLendon RE,et al.PTEN gene mutations are seen in high-grade but not in low-grade gliomas[J].Cancer Res,1997,57:4187-90.

共引文献12

同被引文献40

  • 1殷晓璐,彭颂先,吴浩强.髓母细胞瘤全基因组的等位基因型分析[J].中华病理学杂志,2004,33(5):413-415. 被引量:4
  • 2Giangaspero F, Wellek S, Masuoka J, et al. Stratification of medulloblastoma on the basis of histopathological grading[ J]. Ac- ta Neuropathol, 2006,112 ( 1 ) :5 - 12.
  • 3Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches [ J ]. Neurotherapeu- tics, 2009,6(3) :570 -86.
  • 4Gupta T, Jalali R, Goswaroi S, et al. Early clinical outcomes demonstrate preserved cognitive function in children with average- risk medulloblastoroa when treated with hypeffractionated radiation therapy [ J ]. lnt J Radiat Oncol Biol Phys, 2012,83 (5) : 1534 - 40.
  • 5Gilbertson R J. Medulloblastoma: signalling a change in treatment[J]. Lancet Oncol, 2004,5(4) :209 - 18.
  • 6Roussel M F, Hatten M E. Cerebellum development and medullo- blastoroa[ J ]. CUlT Top Dev Biol, 2011,94:235 - 82.
  • 7Maruyama K, Ochiai A, Akirooto S, et al. Cytoplasmic beta-cate- nin accumulation as a predictor of hematogenous metastasis in hu- roan colorectal cancer[ J]. Ontology, 2000,59(4):302 -9.
  • 8Cadigan K M. Wnt-beta-catenin signalingiJ]. Curr Biol, 2008, 18(20) :R943 -7.
  • 9Wong S C, Lo E S, Chan A K, et al. Nuclear beta catenin as a potential prognostic and diagnostic marker in patients with colorec- tal cancer from Hong Kong[ J ]. Mol Pathol, 2003,56 (6) :347 - 52.
  • 10Carlson J W, Fletcher C D. Immunohistochemistly tot beta-catenin in the differential diagnosis of spindle cell lesions : analysis of a se- ties and review of the literature [ J ]. Histopathology, 2007,51 (4) :509 - 14.

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部